Referências
Principais artigos
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia [internet publication].Texto completo
Smith G, Apperley J, Milojkovic D, et al; British Society for Haematology. A British Society for Haematology guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020 Oct;191(2):171-93.Texto completo Resumo
Hochhaus A, Saussele S, Rosti G, et al; ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl 4):iv41-51.Texto completo Resumo
Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-84.Texto completo Resumo
Artigos de referência
1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022 Jul;36(7):1703-19.Texto completo Resumo
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia [internet publication].Texto completo
3. Smith G, Apperley J, Milojkovic D, et al; British Society for Haematology. A British Society for Haematology guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020 Oct;191(2):171-93.Texto completo Resumo
4. Ch'ang HJ, Tien HF, Wang CH, et al. Comparison of clinical and biologic features between myeloid and lymphoid transformation of Philadelphia chromosome positive chronic myeloid leukemia. Cancer Genet Cytogenet. 1993 Nov;71(1):87-93. Resumo
5. Hehlmann R, Hochhaus A, Baccarani M, et al. Chronic myeloid leukaemia. Lancet. 2007 Jul 28;370(9584):342-50. Resumo
6. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: leukemia - chronic myeloid leukemia (CML). 2024 [internet publication].Texto completo
7. Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):433-42.Texto completo Resumo
8. Ghelani D, Sneed TB, Bueso-Ramos CE, et al. Chapter 4. Chronic myeloid leukemia. In: Kantarjian HM, Wolff RA, Koller CA, eds. MD Anderson manual of medical oncology. New York, NY: McGraw-Hill; 2006:57-74.
9. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med. 1996 May;100(5):555-70. Resumo
10. Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017 Nov 15;123(22):4391-402.Texto completo Resumo
11. Chennamadhavuni A, Lyengar V, Mukkamalla SKR, et al. Leukemia. 2023 Jan 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.Texto completo Resumo
12. Schubauer-Berigan MK, Daniels RD, Fleming DA, et al. Risk of chronic myeloid and acute leukemia mortality after exposure to ionizing radiation among workers at four US nuclear weapons facilities and a nuclear naval shipyard. Radiat Res. 2007 Feb;167(2):222-32. Resumo
13. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994 Dec 15;84(12):4064-77.Texto completo Resumo
14. Hehlmann R. How I treat CML blast crisis. Blood. 2012 Jul 26;120(4):737-47.Texto completo Resumo
15. Ali Hailan YM, Al-Dubai HN, Yassin MA. Chronic myeloid leukemia following exposure to radioactive iodine (I131): a systematic review. Oncology. 2023;101(6):362-8.Texto completo Resumo
16. Cortes JE, Talpaz M, O'Brien S, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006 Mar 15;106(6):1306-15.Texto completo Resumo
17. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-28.Texto completo Resumo
18. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 8;122(6):872-84.Texto completo Resumo
19. Atteya A, Ahmad A, Daghstani D, et al. Evaluation of hepatitis B reactivation among patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer Control. 2020 Jan-Dec;27(1):1073274820976594.Texto completo Resumo
20. Hochhaus A, Saussele S, Rosti G, et al; ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl 4):iv41-51.Texto completo Resumo
21. Lang K, McGarry LJ, Huang H, et al. Mortality and vascular events among elderly patients with chronic myeloid leukemia: a retrospective analysis of linked SEER-Medicare data. Clin Lymphoma Myeloma Leuk. 2016 May;16(5):275-85.e1.Texto completo Resumo
22. Malkan UY, Haznedaroglu IC. Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system. Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5493-506.Texto completo Resumo
23. Nuthulaganti SR, Kandah F, Valentin ME, et al. Blasting into acute coronary syndrome. Cureus. 2021 Nov;13(11):e19589.Texto completo Resumo
24. Ali E, Soliman A, De Sanctis V, et al. Priapism in patients with chronic myeloid leukemia (CML): a systematic review. Acta Biomed. 2021 Jul 1;92(3):e2021193.Texto completo Resumo
25. Rodgers R, Latif Z, Copland M. How I manage priapism in chronic myeloid leukaemia patients. Br J Haematol. 2012 Jul;158(2):155-64. Resumo
26. Soupir CP, Vergilio JA, Dal Cin P, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol. 2007 Apr;127(4):642-50. Resumo
27. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-84.Texto completo Resumo
28. Deau B, Nicolini FE, Guilhot J, et al. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leuk Res. 2011 Jun;35(6):777-82. Resumo
29. Strati P, Kantarjian H, Thomas D, et al. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014 Feb 1;120(3):373-80. Resumo
30. Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015 Jun 11;125(24):3711-9.Texto completo Resumo
31. Deak D, Gorcea-Andronic N, Sas V, et al. A narrative review of central nervous system involvement in acute leukemias. Ann Transl Med. 2021 Jan;9(1):68.Texto completo Resumo
32. Porkka K, Koskenvesa P, Lundán T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008 Aug 15;112(4):1005-12.Texto completo Resumo
33. Copland M. Treatment of blast phase chronic myeloid leukaemia: a rare and challenging entity. Br J Haematol. 2022 Dec;199(5):665-78.Texto completo Resumo
34. Sureda A, Carrasco M, de Miguel M, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica. 2003 Nov;88(11):1213-20. Resumo
35. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002 May 15;99(10):3547-53.Texto completo Resumo
36. Wang Z, Wang X, Wang Z, et al. Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia: a systematic review and meta-analysis. JAMA Netw Open. 2021 Jul 1;4(7):e2120165.Texto completo Resumo
37. Huang J, Cai J, Ye Q, et al. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study. BMJ Open. 2023 Aug 3;13(8):e071456.Texto completo Resumo
38. Gurion R, Gafter-Gvili A, Vidal L, et al. Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? systematic review and meta-analysis. Haematologica. 2013 Jan;98(1):95-102.Texto completo Resumo
39. Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016 Aug;30(8):1648-71.Texto completo Resumo
40. Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma. 2016;57(6):1300-10. Resumo
41. Copland M, Slade D, McIlroy G, et al. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet Haematol. 2022 Feb;9(2):e121-32.Texto completo Resumo
42. Shamroe CL, Comeau JM. Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Pharmacother. 2013 Nov;47(11):1540-6. Resumo
43. Medicines and Healthcare products Regulatory Agency. Ponatinib (Iclusig): reports of posterior reversible encephalopathy syndrome. Oct 2018 [internet publication].Texto completo
44. Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007 Feb 15;109(4):1782-9.Texto completo Resumo
45. Boehm A, Walcherberger B, Sperr WR, et al. Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience. Biol Blood Marrow Transplant. 2011 Jan;17(1):133-40.Texto completo Resumo
46. Khoury HJ, Kukreja M, Goldman JM, et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant. 2012 Jun;47(6):810-6.Texto completo Resumo
47. Savani BN, Montero A, Kurlander R, et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005 Dec;36(11):1009-15. Resumo
48. Zeidner JF, Zahurak M, Rosner GL, et al. The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions? Leuk Lymphoma. 2015 Jan;56(1):128-34.Texto completo Resumo
49. Shanavas M, Messner HA, Kamel-Reid S, et al. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):87-92.Texto completo Resumo
50. Osman AEG, Deininger MW. Chronic myeloid leukemia: modern therapies, current challenges and future directions. Blood Rev. 2021 Sep;49:100825. Resumo
51. Palandri F, Castagnetti F, Testoni N, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica. 2008 Dec;93(12):1792-6.Texto completo Resumo
52. Chang YJ, Wu DP, Lai YR, et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study. J Clin Oncol. 2020 Oct 10;38(29):3367-76.Texto completo Resumo
53. Kurbegov D, Giralt S. Chapter 9. Allogeneic transplantation. In: Kantarjian HM, Wolff RA, Koller CA, eds. MD Anderson manual of medical oncology. New York, NY: McGraw-Hill; 2006:197-218.
54. Taplitz RA, Kennedy EB, Flowers CR. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update summary. J Oncol Pract. 2018 Nov;14(11):692-5.Texto completo Resumo
55. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018 May 10;36(14):1443-53.Texto completo Resumo
56. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hematopoietic cell transplantation [internet publication].Texto completo
57. Chao N. How I treat sinusoidal obstruction syndrome. Blood. 2014 Jun 26;123(26):4023-6.Texto completo Resumo
58. Haguet H, Douxfils J, Mullier F, et al. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf. 2017 Jan;16(1):5-12. Resumo
59. Abruzzese E, Trawinska MM, de Fabritiis P, et al. Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol. 2016 Aug;9(8):781-91. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal